<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04571398</url>
  </required_header>
  <id_info>
    <org_study_id>AH0001</org_study_id>
    <nct_id>NCT04571398</nct_id>
  </id_info>
  <brief_title>A Study of ApricityRx™ for Management of IR-AEs in Patients on Immuno-Oncology Therapy</brief_title>
  <official_title>A Study of ApricityRx™ Digital Therapeutic for Management of Immune-Related Adverse Events in Patients on Immuno-Oncology Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Apricity Health, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Apricity Health, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study of ApricityRx™ for Management of IR-AEs for patients on I-O therapy. Patients currently&#xD;
      receiving immunotherapy will be asked to consent to participate in ApricityRx software&#xD;
      platform mobile telephone application to report symptoms, view educational content in video&#xD;
      form about IO and irAEs and communicate with site study team.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 19, 2019</start_date>
  <completion_date type="Anticipated">October 15, 2023</completion_date>
  <primary_completion_date type="Anticipated">October 15, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate digital therapeutic mobile app to capture and transmit to care team patient-generated health data and access education content on IO and irAEs</measure>
    <time_frame>12 weeks</time_frame>
    <description>Number of times and percentage of study participants who use the app to report patient reported health data during a 12 week period and access education videos.</description>
  </primary_outcome>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Cancer</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>ApricityRx mobile application</intervention_name>
    <description>AE detection and monitoring software</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Subject with a confirmed cancer diagnosis and prescribed checkpoint inhibitor therapy.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Confirmed cancer diagnosis&#xD;
&#xD;
          -  Prescribed treatment with immune-checkpoint inhibitor&#xD;
&#xD;
          -  Age ≥ 18 years&#xD;
&#xD;
          -  Ability to understand and the willingness to sign a written informed consent document.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Uncomfortable with or unwilling to use digital or mobile technology&#xD;
&#xD;
          -  Lack of a smart phone with compatible operating systems: iOS version 10 and above, or&#xD;
             Android 6.0 Marshmallow&#xD;
&#xD;
          -  Presence of any medical, psychological or social condition that, in the opinion of the&#xD;
             investigator, would preclude participation in this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Brian Henick, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Research Nurse Navigator</last_name>
    <phone>212-342-5162</phone>
    <email>cancerclinicaltrials@cumc.columbia.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Columbia University Irving Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 25, 2020</study_first_submitted>
  <study_first_submitted_qc>September 25, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 1, 2020</study_first_posted>
  <last_update_submitted>September 25, 2020</last_update_submitted>
  <last_update_submitted_qc>September 25, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cancer</keyword>
  <keyword>immunotherapy</keyword>
  <keyword>checkpoint inhibitors</keyword>
  <keyword>immune-related adverse events</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

